+

WO2003000842A3 - Nouvelles proteines et acides nucleiques codant pour de telles proteines - Google Patents

Nouvelles proteines et acides nucleiques codant pour de telles proteines Download PDF

Info

Publication number
WO2003000842A3
WO2003000842A3 PCT/US2002/017443 US0217443W WO03000842A3 WO 2003000842 A3 WO2003000842 A3 WO 2003000842A3 US 0217443 W US0217443 W US 0217443W WO 03000842 A3 WO03000842 A3 WO 03000842A3
Authority
WO
WIPO (PCT)
Prior art keywords
small molecule
molecule target
nucleic acids
acids encoding
polynucleotide
Prior art date
Application number
PCT/US2002/017443
Other languages
English (en)
Other versions
WO2003000842A2 (fr
Inventor
Michele L Agee
David W Anderson
Constance Berghs
Stacie J Casman
Elina Catterton
Vincent A Dipippo
Shlomit R Edinger
Andrew Eisen
Karen Ellerman
Esha A Gangolli
Original Assignee
Curagen Corp
Michele L Agee
David W Anderson
Constance Berghs
Stacie J Casman
Elina Catterton
Vincent A Dipippo
Shlomit R Edinger
Andrew Eisen
Karen Ellerman
Esha A Gangolli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curagen Corp, Michele L Agee, David W Anderson, Constance Berghs, Stacie J Casman, Elina Catterton, Vincent A Dipippo, Shlomit R Edinger, Andrew Eisen, Karen Ellerman, Esha A Gangolli filed Critical Curagen Corp
Priority to CA002447941A priority Critical patent/CA2447941A1/fr
Priority to EP02765778A priority patent/EP1578905A2/fr
Priority to JP2003507229A priority patent/JP2005518185A/ja
Publication of WO2003000842A2 publication Critical patent/WO2003000842A2/fr
Publication of WO2003000842A3 publication Critical patent/WO2003000842A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne de nouveaux polynucléotides isolés et des polypeptides cibles à petites molécules codés par les polynucléotides. L'invention concerne également des anticorps de liaison immunospécifique au polypeptide cible à petites molécules ou tout dérivé, variant, mutant ou fragment dudit polypeptide, polynucléotide ou anticorps ainsi que des procédés dans lesquels le polypeptide cible, polynucléotide et anticorps sont utilisés dans la détection et le traitement d'une large gamme de conditions pathologiques. Plus précisément, la présente invention décrit des procédés d'utilisation de protéines exprimées de manière recombinante et/ou endogène dans divers procédés permettant l'identification d'anticorps thérapeutiques et de petites molécules thérapeutiques associés aux maladies.
PCT/US2002/017443 2001-06-04 2002-06-04 Nouvelles proteines et acides nucleiques codant pour de telles proteines WO2003000842A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002447941A CA2447941A1 (fr) 2001-06-04 2002-06-04 Nouvelles proteines et acides nucleiques codant pour de telles proteines
EP02765778A EP1578905A2 (fr) 2001-06-04 2002-06-04 Nouvelles proteines et acides nucleiques codant pour de telles proteines
JP2003507229A JP2005518185A (ja) 2001-06-04 2002-06-04 新規タンパク質およびそれをコード化する核酸

Applications Claiming Priority (72)

Application Number Priority Date Filing Date Title
US29566101P 2001-06-04 2001-06-04
US29560701P 2001-06-04 2001-06-04
US60/295,607 2001-06-04
US60/295,661 2001-06-04
US60/295,573 2001-06-05
US29641801P 2001-06-06 2001-06-06
US29640401P 2001-06-06 2001-06-06
US60/296,418 2001-06-06
US60/296,404 2001-06-06
US29657501P 2001-06-07 2001-06-07
US60/296,575 2001-06-07
US29741401P 2001-06-11 2001-06-11
US60/297,414 2001-06-11
US29757301P 2001-06-12 2001-06-12
US29756701P 2001-06-12 2001-06-12
US60/297,567 2001-06-12
US29828501P 2001-06-14 2001-06-14
US60/298,285 2001-06-14
US29852801P 2001-06-15 2001-06-15
US60/298,528 2001-06-15
US29913301P 2001-06-18 2001-06-18
US60/299,133 2001-06-18
US29923001P 2001-06-19 2001-06-19
US60/299,230 2001-06-19
US29994901P 2001-06-21 2001-06-21
US60/299,949 2001-06-21
US30017701P 2001-06-22 2001-06-22
US60/300,177 2001-06-22
US30088301P 2001-06-26 2001-06-26
US60/300,883 2001-06-26
US30153001P 2001-06-28 2001-06-28
US30155001P 2001-06-28 2001-06-28
US60/301,550 2001-06-28
US60/301,530 2001-06-28
US30295101P 2001-07-03 2001-07-03
US60/302,951 2001-07-03
US30889001P 2001-07-31 2001-07-31
US60/308,890 2001-07-31
US32229701P 2001-09-14 2001-09-14
US60/322,297 2001-09-14
US32466901P 2001-09-25 2001-09-25
US60/324,669 2001-09-25
US33747701P 2001-12-03 2001-12-03
US60/337,477 2001-12-03
US34156201P 2001-12-14 2001-12-14
US60/341,562 2001-12-14
US35865602P 2002-02-21 2002-02-21
US35912202P 2002-02-21 2002-02-21
US60/359,122 2002-02-21
US60/358,656 2002-02-21
US35897802P 2002-02-22 2002-02-22
US35912102P 2002-02-22 2002-02-22
US35903502P 2002-02-22 2002-02-22
US35903402P 2002-02-22 2002-02-22
US60/358,978 2002-02-22
US60/359,035 2002-02-22
US60/359,034 2002-02-22
US60/359,121 2002-02-22
US35996402P 2002-02-27 2002-02-27
US60/359,964 2002-02-27
US36085802P 2002-03-01 2002-03-01
US60/360,858 2002-03-01
US36343002P 2002-03-12 2002-03-12
US36367602P 2002-03-12 2002-03-12
US60/363,676 2002-03-12
US60/363,430 2002-03-12
US37134602P 2002-04-10 2002-04-10
US60/371,346 2002-04-10
US37944402P 2002-05-10 2002-05-10
US60/379,444 2002-05-10
US16061902A 2002-06-03 2002-06-03
US10/160,619 2002-06-03

Publications (2)

Publication Number Publication Date
WO2003000842A2 WO2003000842A2 (fr) 2003-01-03
WO2003000842A3 true WO2003000842A3 (fr) 2005-11-03

Family

ID=34744079

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/017443 WO2003000842A2 (fr) 2001-06-04 2002-06-04 Nouvelles proteines et acides nucleiques codant pour de telles proteines

Country Status (2)

Country Link
JP (1) JP2005518185A (fr)
WO (1) WO2003000842A2 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9295737B2 (en) 2002-03-01 2016-03-29 Bracco Suisse Sa Targeting vector-phospholipid conjugates
US9408926B2 (en) 2002-03-01 2016-08-09 Bracco Suisse S.A. KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US9446155B2 (en) 2002-03-01 2016-09-20 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US9562049B2 (en) 2012-12-21 2017-02-07 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041494B2 (en) 2000-11-15 2006-05-09 Icagen, Inc. DNA encoding Slo2 and Slo4, potassium channel
US6815181B2 (en) 2001-07-09 2004-11-09 Applera Corporation Nucleic acid molecules encoding human secreted hemopexin-related proteins
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
ES2692166T3 (es) 2003-03-03 2018-11-30 Dyax Corp. Péptidos que se unen específicamente al receptor de HGF (cMet) y usos de los mismos
SG10201701737XA (en) 2003-11-06 2017-04-27 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
EP1753463A2 (fr) 2004-06-01 2007-02-21 Genentech, Inc. Conjugues de medicaments anticorps et procedes correspondants
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
ES2669510T3 (es) 2004-09-23 2018-05-28 Genentech, Inc. Anticuerpos y conjugados modificados por ingeniería genética con cisteína
JP2006217859A (ja) * 2005-02-10 2006-08-24 Japan Health Science Foundation アルツハイマー病の治療薬または予防薬のスクリーニング方法、およびアルツハイマー病を診断する方法、アルツハイマー病発症の危険度を予測する方法
EP1849877A1 (fr) * 2006-04-24 2007-10-31 Erasmus University Medical Center Rotterdam Histoire réplicative de sous-ensembles de lymphocytes T et B
DE102007017433A1 (de) * 2007-04-03 2008-10-09 Eberhard-Karls-Universität Tübingen Universitätsklinikum PIKfyve als pharmakologisches Target zur Behandlung von glucosestoffwechselassoziierten Krankheiten
WO2011031870A1 (fr) 2009-09-09 2011-03-17 Centrose, Llc Conjugués médicamenteux ciblés à visée extracellulaire
EP2528625B1 (fr) 2010-04-15 2013-07-10 Spirogen Sàrl Pyrrolobenzodiazépines et conjugués de celles-ci
SG185428A1 (en) 2010-06-08 2012-12-28 Genentech Inc Cysteine engineered antibodies and conjugates
US20120121615A1 (en) 2010-11-17 2012-05-17 Flygare John A Alaninyl maytansinol antibody conjugates
WO2012112955A2 (fr) 2011-02-17 2012-08-23 The Trustees Of Columbia University In The City Of New York Procédés d'identification de sujets présentant un risque génétique de développer une néphropathie à iga
CA2833212C (fr) 2011-05-12 2020-06-09 Genentech, Inc. Reaction multiple de surveillance du procede lc-ms/ms pour detecter les anticorps therapeutiques dans les echantillons d'animaux par des peptides de signature du cadre
JP5864918B2 (ja) * 2011-07-06 2016-02-17 国立大学法人東北大学 オートタキシンアイソフォーム特異的抗体および検出方法
JP6104257B2 (ja) 2011-10-14 2017-03-29 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピンおよびそのコンジュゲート
WO2013130093A1 (fr) 2012-03-02 2013-09-06 Genentech, Inc. Biomarqueurs pour un traitement à base de composés chimiothérapeutiques anti-tubuline
HUE041274T2 (hu) 2012-10-12 2019-05-28 Adc Therapeutics Sa Pirrolobenzodiazepin-anti-PSMA-antitest konjugátumok
US10695433B2 (en) 2012-10-12 2020-06-30 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
KR101995621B1 (ko) 2012-10-12 2019-07-03 에이디씨 테라퓨틱스 에스에이 피롤로벤조디아제핀-항-cd22 항체 컨주게이트
WO2014057119A1 (fr) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Conjugués anticorps - pyrrolobenzodiazépine
MX372691B (es) 2012-10-12 2020-05-28 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas.
ES2680153T3 (es) 2012-10-12 2018-09-04 Adc Therapeutics Sa Conjugados de anticuerpos anti-PSMA-pirrolobenzodiazepinas
PT2906298T (pt) 2012-10-12 2018-12-28 Medimmune Ltd Conjugados de pirrolobenzodiazepina-anticorpos
CN105209077B (zh) 2013-03-13 2019-06-11 麦迪穆有限责任公司 吡咯并苯并二氮杂卓以及其结合物
JP6340019B2 (ja) 2013-03-13 2018-06-06 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びそのコンジュゲート
AR096287A1 (es) 2013-03-13 2015-12-23 Spirogen Sàrl Pirrolobenzodiacepinas y conjugados
WO2014169294A1 (fr) * 2013-04-12 2014-10-16 The Trustees Of Columbia University In The City Of New York Mutations dans dstyk provoquant des malformations dominantes dans les voies urinaires
EP3033111B1 (fr) 2013-08-12 2019-03-13 Genentech, Inc. Conjugués anticorps-médicament dimérique 1-(chlorométhyl)-2,3-dihydro-1 h-benzo [e]indole, et méthodes d'utilisation et de traitement
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
EP3054986B1 (fr) 2013-10-11 2019-03-20 Medimmune Limited Conjugués anticorps-pyrrolobenzodiazépine
EP3054985B1 (fr) 2013-10-11 2018-12-26 Medimmune Limited Conjugués anticorps-pyrrolobenzodiazépine
US10010624B2 (en) 2013-10-11 2018-07-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
WO2015095212A1 (fr) 2013-12-16 2015-06-25 Genentech, Inc. Composés conjugués anticorps-médicament dimérique à base de 1-(chlorométhyl)-2,3-dihydro-1 h-benzo [e]indole, et méthodes d'utilisation et de traitement
PE20161394A1 (es) 2013-12-16 2017-01-06 Genentech Inc Compuestos peptidomimeticos y sus conjugados de anticuerpo-farmaco
KR102354207B1 (ko) 2013-12-16 2022-01-20 제넨테크, 인크. 펩티드모방체 화합물 및 그의 항체-약물 접합체
EP3193940A1 (fr) 2014-09-10 2017-07-26 Medimmune Limited Pyrrolobenzodiazépines et leurs conjugués
EP3191134B1 (fr) 2014-09-12 2019-11-20 Genentech, Inc. Intermédiaires disulfure d'anthracycline, conjugué anticorps-médicaments et procédés
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
JP2017531620A (ja) 2014-09-12 2017-10-26 ジェネンテック， インコーポレイテッド システイン操作抗体及びコンジュゲート
EP3194400A1 (fr) 2014-09-17 2017-07-26 Genentech, Inc. Pyrrolobenzodiazépines et conjugués à base de disulfure d'anticorps associés
WO2016072936A1 (fr) * 2014-11-03 2016-05-12 Nanyang Technological University Nouveaux systèmes d'expression de recombinant
BR112017011111A2 (pt) 2014-11-25 2017-12-26 Adc Therapeutics Sa conjugados de pirrolobenzodiazepina-anticorpo
CA2969689A1 (fr) 2014-12-03 2016-06-09 Genentech, Inc. Composes d'amine quaternaire et conjugues anticorps-medicament de ceux-ci
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
MA45326A (fr) 2015-10-20 2018-08-29 Genentech Inc Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
US20170315132A1 (en) 2016-03-25 2017-11-02 Genentech, Inc. Multiplexed total antibody and antibody-conjugated drug quantification assay
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
JP2019522633A (ja) 2016-05-20 2019-08-15 ジェネンテック， インコーポレイテッド Ｐｒｏｔａｃ抗体コンジュゲート及び使用方法
JP7022080B2 (ja) 2016-05-27 2022-02-17 ジェネンテック， インコーポレイテッド 部位特異的抗体－薬物複合体の特徴付けのための生化学分析的方法
WO2017214024A1 (fr) 2016-06-06 2017-12-14 Genentech, Inc. Médicaments conjugués d'anticorps silvestrol et procédés d'utilisation
CN109689111B (zh) 2016-08-11 2024-04-05 基因泰克公司 吡咯并苯并二氮杂䓬前药及其抗体缀合物
JP7050770B2 (ja) 2016-10-05 2022-04-08 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗体薬物コンジュゲートの調製方法
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
MX375569B (es) 2017-02-08 2025-03-04 Adc Therapeutics Sa Conjugados de pirrolobenzodiazepinas y anticuerpos
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
SMT202200490T1 (it) 2017-04-18 2023-01-13 Medimmune Ltd Coniugati di pirrolobenzodiazepina
AU2018253948B2 (en) 2017-04-20 2024-08-01 Adc Therapeutics Sa Combination therapy with an anti-AXL Antibody-Drug Conjugate
JP7145891B2 (ja) 2017-06-14 2022-10-03 アーデーセー セラピューティクス ソシエテ アノニム 抗ｃｄ１９ ａｄｃを投与するための投与レジメ
KR102270107B1 (ko) 2017-08-18 2021-06-30 메디뮨 리미티드 피롤로벤조디아제핀 컨쥬게이트
BR112020004307A2 (pt) 2017-09-20 2020-11-10 Ph Pharma Co., Ltd. análogos de tailanestatina
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
JP2022505450A (ja) 2018-10-24 2022-01-14 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト コンジュゲート化された化学的分解誘導物質および使用方法
EP3894427A1 (fr) 2018-12-10 2021-10-20 Genentech, Inc. Peptides de photoréticulation pour conjugaison spécifique de site à des protéines contenant fc
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
MX2021010477A (es) 2019-03-15 2021-10-01 Medimmune Ltd Dimeros de azetidobenzodiazepina y conjugados que los comprenden para uso en el tratamiento de cancer.
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
AU2021362997A1 (en) 2021-11-03 2024-05-16 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody
TW202432187A (zh) 2022-12-23 2024-08-16 美商建南德克公司 小腦蛋白降解劑結合物及其用途
WO2024220546A2 (fr) 2023-04-17 2024-10-24 Peak Bio, Inc. Anticorps et conjugués anticorps-médicament et procédés d'utilisation, processus synthétiques et intermédiaires

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIOCHEM. BIOPHYS. ACTA 1519, vol. 1-2, 2001, pages 117 - 121 *
DATABASE GENBANK [online] VIGETTI D. ET AL: "Molecular cloning of mouse allantoicase cDNA", XP002991050, Database accession no. (AF278712) *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9295737B2 (en) 2002-03-01 2016-03-29 Bracco Suisse Sa Targeting vector-phospholipid conjugates
US9381258B2 (en) 2002-03-01 2016-07-05 Bracco Suisse S.A. Targeting vector-phospholipid conjugates
US9408926B2 (en) 2002-03-01 2016-08-09 Bracco Suisse S.A. KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US9446155B2 (en) 2002-03-01 2016-09-20 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US9562049B2 (en) 2012-12-21 2017-02-07 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases

Also Published As

Publication number Publication date
WO2003000842A2 (fr) 2003-01-03
JP2005518185A (ja) 2005-06-23

Similar Documents

Publication Publication Date Title
WO2003000842A3 (fr) Nouvelles proteines et acides nucleiques codant pour de telles proteines
WO2002081498A3 (fr) Nouvelles proteines et acides nucleiques codant pour ces proteines
WO2003010327A3 (fr) Nouvelles proteines et acides nucleiques les codant
WO2001036645A3 (fr) Nouveaux polypeptides et acides nucleiques codant les memes
WO2003040325A3 (fr) Nouvelles proteines et acides nucleiques codant ces proteines
WO2002072757A3 (fr) Proteines et acides nucleiques codant pour ces proteines
WO2000053742A3 (fr) Polynucleotides et proteines codees par ceux-ci
WO2001049729A8 (fr) Nouveaux polypeptides et acides nucleiques codant ceux-ci
WO2003083046A3 (fr) Nouvelles proteines et acides nucleiques codant pour de telles proteines
WO2003023001A3 (fr) Nouvelles proteines et acides nucleiques codant ces proteines
WO2003029424A3 (fr) Nouvelle proteines et acides nucleiques codant celles-ci
WO2003064628A3 (fr) Mandrin a vide faisant intervenir un materiau fritte et procede de fabrication
WO2001074856A3 (fr) Polypeptides de type wnt-7b et acides nucleiques codant pour ceux-ci
WO2002002625A3 (fr) Nouveaux facteurs de croissance des fibroblastes et acides nucleiques codant pour ces memes facteurs
WO2003102159A3 (fr) Nouvelles proteines et nouveaux acides nucleiques codant pour ces proteines
WO2001070978A3 (fr) Nouveaux polypeptides et acides nucleiques codant ces polypeptides
WO2001062928A3 (fr) Polypeptides et acides nucleiques codant pour
WO2003025147A3 (fr) Nouveaux polynucleotides et proteines codees par ceux-ci
WO2001061009A3 (fr) Nouveaux polypeptides et acides nucleiques les codant
WO2001044473A3 (fr) Polypeptides et acides nucleiques codant pour ces polypeptides
WO2004048512A3 (fr) Nouvelles proteines et acides nucleiques codant pour ces proteines
WO2001036638A3 (fr) Nouveaux polypeptides et acides nucleiques codant pour ces polypeptides
WO2000061754A3 (fr) Nouvelles proteines humaines et polypeptides codant pour ces proteines
WO2003057854A3 (fr) Nouvelles proteines et acides nucleiques codant ces dernieres
WO2003076642A3 (fr) Nouvelles proteines et acides nucleiques codant ces proteines

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US US US US US US US US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2002329178

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2447941

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003507229

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002765778

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2004104635

Country of ref document: RU

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 2002765778

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002765778

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载